AT2S2 Antibody
Description
Overview of AT2 Receptor Antibodies
AT2 receptor antibodies target the angiotensin II type 2 receptor (AGTR2), a G protein-coupled receptor that counterbalances the hypertensive and proliferative effects of angiotensin II via the AT1 receptor . These antibodies are primarily used in research to study cardiovascular, renal, and neurological systems.
Validation Challenges
-
Lack of Specificity: Three major commercial AT2 antibodies (AAR-012, sc-9040, 2818-1) fail specificity tests in knockout models, producing identical immunoreactive bands in AT2R⁻/⁻ and wild-type tissues .
-
Species Limitations: AAR-012 does not cross-react with human AT2R , limiting translational applications.
Clinical and Therapeutic Implications
While no AT2-targeting antibodies are currently FDA-approved, research-grade antibodies inform:
-
Hypertension Mechanisms: AT2 autoantibodies reduce systolic blood pressure responses to angiotensin II by 43% in immunized rabbits .
-
Neurological Pathways: AT2 receptors localize to paraventricular hypothalamic neurons, suggesting roles in central blood pressure regulation .
Recommendations for Researchers
-
Validation: Combine antibody-based detection with competitive radioligand binding or mRNA analysis .
-
Epitope Selection: Prefer antibodies targeting extracellular domains (e.g., AAR-012) for cell surface studies .
-
Species Matching: Use ab92445 for human studies due to AAR-012's lack of human reactivity .
